Proteonomix, Inc. (PROT) Examines Licensing of Diabetes Stem Cell Technology
17 Outubro 2011 - 1:30PM
Marketwired
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on
developing therapeutics based upon the use of human cells and their
derivatives, announced today that it has decided to examine the
possibility of licensing its stem cell diabetes related technology
to another company in light of continued progress toward its trial
of UMK-121, its stem cell treatment for patients awaiting liver
transplant to overcome End Stage Liver Disease ("ESLD").
Michael Cohen, President of the Company, stated: "Since we
continue our rapid progress toward the commencement of our trial of
UMK-121, we have decided to explore the possible licensing of our
diabetes related applications of our stem cell technology to
another company. This strategic decision is being made in
recognition of the increasing breadth of our technology and the
need for additional capital and management resources to effectively
deal with the massive ramifications of the diabetes applications of
the stem cell technology that we have developed."
Mr. Cohen continued: "We have been approached by one group that
has expressed interest in exploring such a possibility and we will
follow through with this in the coming weeks. Meanwhile we will
seek out others interested in a similar transaction keeping in mind
at all times that any such deal would have to provide immediate
benefit to our shareholders."
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix Family of companies includes
Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR
Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has
developed an anti-aging line of skin care products. StromaCel, Inc.
develops therapeutic modalities for the treatment of Cardiovascular
Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating
subsidiary. Proteonomix Regenerative Translational Medicine
Institute, Inc. ("PRTMI") intends to focus on the translation of
promising research in stem cell biology and cellular therapy to
clinical applications of regenerative medicine. Proteonomix intends
to create and dedicate a subsidiary to each of its technologies.
Please also visit http://www.proteonomix.com/,
http://www.proteoderm.com/, http://www.otcqb.com/ and
http://www.sec.gov/.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Proteonomix, Inc. Michael Cohen CEO Phone:
+1-973-544-6116 Email: Email Contact
Proteonomix (CE) (USOTC:PROT)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Proteonomix (CE) (USOTC:PROT)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Proteonomix Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Proteonomix